PL2380584T3 - Sposób do immunostymulacji - Google Patents

Sposób do immunostymulacji

Info

Publication number
PL2380584T3
PL2380584T3 PL11166835T PL11166835T PL2380584T3 PL 2380584 T3 PL2380584 T3 PL 2380584T3 PL 11166835 T PL11166835 T PL 11166835T PL 11166835 T PL11166835 T PL 11166835T PL 2380584 T3 PL2380584 T3 PL 2380584T3
Authority
PL
Poland
Prior art keywords
oligonucleotide
steroid
immunostimulatory method
immunostimulatory
pharmaceuticals
Prior art date
Application number
PL11166835T
Other languages
English (en)
Inventor
Robert Löfberg
Stein Oliver Von
Arezou Zargari
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of PL2380584T3 publication Critical patent/PL2380584T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
PL11166835T 2005-07-01 2006-06-29 Sposób do immunostymulacji PL2380584T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69617305P 2005-07-01 2005-07-01
EP10162989.7A EP2269622B1 (en) 2005-07-01 2006-06-29 CpG oligonucleotides used for enhancing steroid activity in a steroid dependent patient
EP11166835.6A EP2380584B1 (en) 2005-07-01 2006-06-29 Immunostimulatory method
EP06748068A EP1901759B1 (en) 2005-07-01 2006-06-29 Immunostimulatory method

Publications (1)

Publication Number Publication Date
PL2380584T3 true PL2380584T3 (pl) 2014-03-31

Family

ID=37604739

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11166835T PL2380584T3 (pl) 2005-07-01 2006-06-29 Sposób do immunostymulacji
PL10162989T PL2269622T3 (pl) 2005-07-01 2006-06-29 Sposób do modulowania wrażliwości na steroidy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10162989T PL2269622T3 (pl) 2005-07-01 2006-06-29 Sposób do modulowania wrażliwości na steroidy

Country Status (14)

Country Link
US (2) US8258107B2 (pl)
EP (3) EP2269622B1 (pl)
JP (3) JP5074392B2 (pl)
AT (1) ATE476193T1 (pl)
AU (1) AU2006266503B2 (pl)
CA (1) CA2612162C (pl)
CY (1) CY1114965T1 (pl)
DE (1) DE602006015963D1 (pl)
DK (2) DK2269622T3 (pl)
ES (3) ES2450593T3 (pl)
PL (2) PL2380584T3 (pl)
PT (1) PT2269622E (pl)
SI (2) SI2269622T1 (pl)
WO (1) WO2007004977A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330884T3 (es) * 2005-07-01 2009-12-16 Index Pharmaceuticals Ab Modulacion de la respuesta a los esteroides.
PL2380584T3 (pl) * 2005-07-01 2014-03-31 Index Pharmaceuticals Ab Sposób do immunostymulacji
EP1940472A1 (en) * 2005-10-28 2008-07-09 Index Pharmaceuticals AB Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
KR20100068422A (ko) * 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
CA2708267C (en) * 2007-12-14 2016-05-10 Index Pharmaceuticals Ab Method for predicting the response to a therapy
WO2009154565A1 (en) * 2008-06-18 2009-12-23 Index Pharmaceuticals Ab Combination therapies against cancer
JP5746038B2 (ja) * 2008-11-04 2015-07-08 インデックス・ファーマシューティカルズ・アクチエボラーグ Ｃｎｓの炎症性疾患の治療のための化合物および方法
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2596806A1 (en) 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
EP3511416A1 (en) 2012-05-16 2019-07-17 Translate Bio MA, Inc. Compositions and methods for modulating gene expression
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
EP3271460A4 (en) 2015-03-17 2019-03-13 The General Hospital Corporation RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1)
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201707500D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy
GB201707503D0 (en) 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201807312D0 (en) * 2018-05-03 2018-06-20 Index Pharmaceuticals Ab Formulation
EP4147688A1 (en) * 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (pl) 1992-07-23 1995-04-01 Tri Clover Inc
CA2105595A1 (en) 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
SE9602300D0 (sv) * 1996-06-11 1996-06-11 Karolinska Innovations Ab New composition and methods
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
JP2002510644A (ja) 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
EP1077708A1 (en) 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
CA2328406A1 (en) 1998-05-14 1999-11-18 Hermann Wagner Methods for regulating hematopoiesis using cpg-oligonucleotides
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO2000006588A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
TR200200797T2 (tr) 1999-09-25 2002-10-21 University Of Iowa Research Foundation İmmünostimülatör nükleik asitler
EP1688147A1 (en) 1999-09-27 2006-08-09 Coley Pharmaceutical Group, Inc. Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
NZ517928A (en) 1999-09-27 2004-09-24 Coley Pharm Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US6649341B1 (en) 2000-04-19 2003-11-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Human glucocorticoid receptor 1A promoter and splice variants
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20020198165A1 (en) 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
CA2419894A1 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh Process for high throughput screening of cpg-based immuno-agonist/antagonist
US6294382B1 (en) 2000-11-27 2001-09-25 Isis Pharmaceuticals, Inc. Antisense modulation of SRC-1 expression
US20030055014A1 (en) 2000-12-14 2003-03-20 Bratzler Robert L. Inhibition of angiogenesis by nucleic acids
JP2002257827A (ja) 2001-03-01 2002-09-11 Jenokkusu Soyaku Kenkyusho:Kk ステロイド応答性の検査方法
US20030050268A1 (en) 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
WO2002085308A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
WO2003031573A2 (en) 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
WO2003030934A2 (en) 2001-10-06 2003-04-17 Merial Limited Cpg formulations and related methods
JP2005526497A (ja) 2002-02-04 2005-09-08 ビオミラ，インコーポレーテッド 免疫刺激性、共有結合性脂質化オリゴヌクレオチド
AU2003230806B2 (en) * 2002-04-04 2009-05-07 Zoetis Belgium S.A. Immunostimulatory G,U-containing oligoribonucleotides
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
JP2006516099A (ja) 2002-12-23 2006-06-22 ダイナバックス テクノロジーズ コーポレイション 分枝状の免疫調節化合物及び該化合物の使用方法
ES2381309T3 (es) 2002-12-23 2012-05-25 Dynavax Technologies Corporation Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos
KR101123489B1 (ko) 2003-01-16 2012-03-28 이데라 파마슈티칼즈, 인코포레이티드 개질된 면역자극성 디뉴클레오티드를 이용한 올리고뉴클레오티드-기재 화합물의 면역자극 특성의 조절
JP5022028B2 (ja) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート
EP1608403A2 (en) 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
CA2526212C (en) 2003-05-16 2013-08-27 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
US20050158325A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
CN1918293A (zh) 2004-02-20 2007-02-21 莫洛根股份公司 用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
SE0400399D0 (sv) 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
WO2005081847A2 (en) 2004-02-20 2005-09-09 Hybridon, Inc. Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
NZ552522A (en) 2004-06-15 2009-04-30 Idera Pharmaceuticals Inc Immunostimulatory oligonucleotide multimers
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
AU2005282889B2 (en) 2004-09-01 2012-03-15 Dynavax Technologies Corporation Methods and conpositions for inhibition of innate immune responses and autoimmunity
WO2006110607A2 (en) 2005-04-08 2006-10-19 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
PL2380584T3 (pl) * 2005-07-01 2014-03-31 Index Pharmaceuticals Ab Sposób do immunostymulacji
ES2330884T3 (es) * 2005-07-01 2009-12-16 Index Pharmaceuticals Ab Modulacion de la respuesta a los esteroides.

Also Published As

Publication number Publication date
PT2269622E (pt) 2014-03-20
ES2450593T3 (es) 2014-03-25
EP1901759B1 (en) 2010-08-04
ES2442090T3 (es) 2014-02-10
AU2006266503B2 (en) 2011-12-08
DE602006015963D1 (de) 2010-09-16
ES2349617T3 (es) 2011-01-07
EP2380584B1 (en) 2013-10-16
CA2612162C (en) 2016-05-17
PL2269622T3 (pl) 2014-05-30
CA2612162A1 (en) 2007-01-11
ATE476193T1 (de) 2010-08-15
EP1901759A1 (en) 2008-03-26
JP5074392B2 (ja) 2012-11-14
US20120277293A1 (en) 2012-11-01
SI2380584T1 (sl) 2014-04-30
JP2012232988A (ja) 2012-11-29
WO2007004977A1 (en) 2007-01-11
DK2380584T3 (da) 2014-01-20
EP2269622B1 (en) 2013-12-25
US8592390B2 (en) 2013-11-26
SI2269622T1 (sl) 2014-05-30
AU2006266503A1 (en) 2007-01-11
DK2269622T3 (en) 2014-03-24
CY1114965T1 (el) 2016-12-14
EP2380584A1 (en) 2011-10-26
US20100234449A1 (en) 2010-09-16
JP2008544983A (ja) 2008-12-11
EP2269622A1 (en) 2011-01-05
US8258107B2 (en) 2012-09-04
JP2012232989A (ja) 2012-11-29
JP5945176B2 (ja) 2016-07-05

Similar Documents

Publication Publication Date Title
SI2380584T1 (sl) Imunostimulatorni postopek
PL381247A1 (pl) Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
IL188475A0 (en) Pyrido [2,3-d]pyrimidine-2,4-diamine compounds as ptpib inhibitors
ZA200702130B (en) Memantine for the treatment of childhood behavioral disorders
IL219721A0 (en) Charged lipoprotein complexes, pharmaceutical compositions comprising them and their uses
PT2050447T (pt) Forma de dosagem oral contendo entacapona
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
IL173908A0 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
UA85559C2 (en) Aminobenzophenone compounds
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
MX2007012702A (es) Uso de anticuerpos cd25 en inmunoterapia.
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies
PT2179737E (pt) Método para modular a capacidade de resposta aos esteróides
IL178435A0 (en) Beta-carbolines useful for treating inflammatory disease
MX2011011618A (es) Agentes terapeuticos 713.
PL2046394T3 (pl) Zastosowanie sekwencji kwasów nukleinowych do leczenia chorób neurologicznych i psychiatrycznych, wektory i kompozycje
TW200640467A (en) Compounds and uses thereof
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
PL1874739T3 (pl) Farmaceutycznie czynne diazepany
PL2036575T3 (pl) Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością
EP2091562A4 (en) IL-18 VACCINE FOR THE TREATMENT OF VARIOUS INFLAMMATORY DISEASES
GB0506708D0 (en) Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions